Skip to main content
Joaquin (Bellmunt) Bellmunt Molins, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

Joaquin(Bellmunt)Bellmunt MolinsMDPhD

Oncology • Boston, MA

Genitourinary Oncology

Associate Professor, Medicine, Harvard Medical School, Director Bladder Cancer Center, Medicine, Beth Israel Deaconess Medical Center.

Join to view full profile

Dr. Bellmunt Molins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bellmunt Molins' full profile

Already have an account?

Summary

  • Dr. Joaquim Bellmunt is Associate Professor of Medicine at Harvard Medical School and Attending Physician of Solid Tumor Oncology at Beth Israel Deaconess Medical Center. He also serves as the Director of the Bladder Cancer Program at BIDMC , Harvard University, Boston working as part of a multidisciplinary team to provide complete care for patients with genitourinary malignancies. He is past chairman of the Committee of Advanced Bladder Cancer in the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group (EORTC-GU). He is co-founder and has been President of the Spanish Group for Treatment of Genitourinary Tumors (SOGUG). Dr Bellmunt's efforts have largely centered on improving the care of patients with genitourinary malignancies focusing on bladder and renal cell carcinoma.

    His areas of interest in genitourinary oncology include the development of drugs directed to novel therapeutic targets and early clinical and translational research in the field of growth factor receptors and angiogenesis. While his research interests are focused on bladder cancer, he has extensive experience treating prostate, penile, and kidney cancer. He serves on International committees focused on improving the treatments of genitourinary and bladder cancers. He is a member of the Editorial Board of the Journal of Clinical Oncology and European Urology.

    He has been chairing two of the larger multicenter international trials of new drugs in the treatment of bladder cancer, in one of them, leading to the establishment of a new drug for bladder cancer patients. Dr Bellmunt's research focuses on clinical trials with aims to improve the treatment of patients with advanced bladder (urothelial) tumors as well as the development of novel agents for this disease. Dr Bellmunt is currently involved in collaborative efforts with basic scientists to analyze clinical, tissue, and biomarkers to optimize the administration

Education & Training

  • Autonomous University of Barcelona Faculty of Medicine
    Autonomous University of Barcelona Faculty of MedicineClass of 1982, MD

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2013 - 2025
  • American Board of Internal Medicine (ABIM)Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Hospital Affiliations

Dr. Joaquin Bellmunt Molins, Dr. Joaquin Bellmunt Molins, MD, Dr. J Bellmunt Molins